SCNI — Scinai Immunotherapeutics Ltd.

Summary of SCNI Q2 2024 Earnings Call

1. Key Financial Results and Metrics

• R&D Expenses: $2.79 million for the first half of 2024, down from $3.45 million in the same period last year, primarily due to reduced salaries and subcontractor use.
• Marketing and G&A Expenses: $1 million for the first half of 2024, significantly lower than $2.3 million in the previous year, attributed to cuts in salaries and professional services.
• Financial Expenses: Reduced to $0.53 million from $1.5 million, due to prior reclassification of warrants and loan revaluation.
• Net Loss: $4.48 million for the first half of 2024, an improvement from $7.28 million in the previous year.
• Cash Position: $3.21 million as of June 30, 2024, down from $7.63 million a year prior.
• Shareholder Equity: Expected to improve significantly from negative $7.28 million to approximately $12 million positive post-EIB restructuring.

2. Strategic Updates and Business Highlights

• Business Units: Scinai operates two units: R&D focusing on novel VHH antibodies and a CDMO unit for drug development services.
• CDMO Revenue: First revenues reported from the CDMO unit, with a target of $1.25 million for 2024. Generated $600,000 in work orders since January 2024.
• Regulatory Progress: Received positive feedback from the Paul Erlich Institute for their anti-IL-17 AF nanoAb, with plans for a Phase 1/2a clinical trial expected to start in late 2025.
• Investment Commitment: Secured a $2 million equity commitment from Daniel Stone, enhancing liquidity and investor confidence.

3. Forward Guidance and Outlook

• CDMO Growth: Anticipated material revenue growth from the CDMO unit, with a long-term capacity target of $24 million in annual revenues.
• Clinical Trials: Plans to commence a proof of concept study in animals in September 2024, followed by toxicity studies and a Phase 1/2a trial in late 2025.
• Strategic Partnerships: Aiming to engage larger pharmaceutical companies for potential partnerships and sublicensing agreements to support clinical trials and commercialization.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: Despite reductions in expenses, the company’s cash position has decreased, raising concerns about sustainability without further funding.
• Negative Shareholder Equity: Current negative equity could deter potential investors until the EIB restructuring is completed.
• Regulatory Risks: While positive feedback has been received, the path to clinical trials and eventual commercialization remains fraught with regulatory challenges.

5. Notable Q&A Insights

• Long-term Share Price and Growth: CEO Amir Reichman expressed confidence in Scinai’s undervaluation and potential for growth, citing a strong pipeline and strategic positioning.
• Clinical and Commercial Potential: Emphasized the importance of the upcoming animal study to refine dosing schedules before human trials, aiming for cost-effective and timely market entry.
• Regulatory Strategy: Highlighted the company's proactive approach in working with experienced regulatory advisors to navigate the approval process efficiently.

This summary encapsulates the key points from SCNI's Q2 2024 earnings call, reflecting both the company's progress and the challenges it faces moving forward.